| الوصف: |
To use multimodal assessment (fluorescein angiography [FA], color fundus photography [CFP], and/or spectral domain OCT [SD-OCT]) to reevaluate macular atrophy (MA) and macular neovascularization (MNV) type in the HARBOR trial according to the Consensus on Neovascular AMD Nomenclature criteria; and to determine if there are any associations between baseline demographic factors, ocular characteristics, and/or treatment for neovascular age-related macular degeneration (nAMD) and the development of MA by month 24.Post hoc analysis of the phase 3, randomized, multicenter, double-masked, controlled HARBOR trial (NCT00891735).Nine hundred twenty-two study eyes and 919 fellow eyes from the HARBOR trial.This post hoc analysis included patients with multimodal assessments on FA, CFP, and SD-OCT at baseline. A risk analysis for the development of MA was performed by multimodal assessment and SD-OCT on study eyes without MA at baseline that had completed SD-OCT assessments for MA at month 24.Development of MA in study eyes at month 24 and a risk analysis for developing MA at month 24 in study eyes that had no MA at baseline, as assessed by multimodal assessment.Of 1097 patients in the HARBOR trial with nAMD and active subfoveal MNV, a total of 922 study eyes and 919 fellow eyes were included in the multimodal analysis of MNV. MA assessment was performed on SD-OCT. Of these, 593 had no baseline MA and were included in the risk analysis for developing MA. In eyes with no detectable MA at baseline, a larger proportion of eyes with any MNV type 3 (including mixed type) at baseline developed new MA at month 24 (49.2%) than eyes with MNV type 1 (26.5%), type 2 (29.1%), or mixed type 1 and 2 (34.6%). MNV type 3 and fellow eye MA were identified as risk factors for new MA development at month 24.MNV type 3 was a strong risk factor for new MA development at month 24, with fellow eye MA also being identified as a predictor. No other variables, including ranibizumab treatment, were identified as risk factors for new MA development. |
